News

Ideas That Generate Results

Antibody Dug Conjugates have been attracting a lot of interest from researchers and pharma giants across the world. This surge in interest can be attributed to improved technologies that have enhanced the potential of ADCs. Pharma giants are indulging in strategic moves such as collaborations, mergers and acquisitions, being made in order to combine technologies and capabilities from other companies with inherent ones for the development of ADCs. For example, Sorrento Therapeutics recently acquired Concortis Biosystems, a deal which will provide Sorrento with a technology platform for the production of ADCs.
 
According to our report, “Global Antibody Drug Conjugate Market Outlook 2018”, backed by improved understanding and better technology, the ADC market is anticipated to reach US$ 3.45 Billion by 2018. Our report analyzes the market for Adcetris and Kadcyla in detail. Market potential for these drugs has been estimated keeping in mind the fact that these drugs are being tested in clinical trials for various indications apart from the ones for which they are approved.
 
The report also provides an insight into the key ADCs that are currently in pipeline. Apart from new drug candidates, previously approved drugs are also being tested for other indications. Later in the report, strategic activities such as mergers, acquisitions and collaborations that have taken place over ADC have been provided.
 
At the end, major players of ADC market have been discussed. A brief business overview of every player has been provided alongwith their product and pipeline portfolio and recent developments. A comparative strength and weakness analysis of these players has been done. Overall, the report will prove to be a complete source of knowledge and analysis for clients and potential investors.
 
For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM667.htm
 
Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm